Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/IDR.S39186 http://scihub22266oqcxt.onion/10.2147/IDR.S39186 C4554481!4554481!26345624     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Infect+Drug+Resist 2015 ; 8 (ä): 297-309 Nephropedia Template TP {{tp|p=26345624|t=2015. Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibiotics |pdf=|usr=}}{{26345624}} gab.com Text Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibiotics JO: Infect Drug Resist http://www.kidney.de/pget.php?&tw=1&pmid=26345624 #FOAvip Since the first New Delhi metallo-beta-lactamase (NDM) report in 2009, NDM has spread globally causing various types of infections. NDM-positive organisms produce in vitro resistance phenotypes to carbapenems and many other antimicrobials. It is thus surprising that the literature examining clinical experiences with NDM does not report corresponding poor clinical outcomes. There are many instances where good clinical outcomes are described, despite a mismatch between administered antimicrobials and resistant in vitro susceptibilities. Available in vitro data for either monotherapy or combination therapy does not provide an explanation for these observations. However, animal studies do begin to shed more light on this phenomenon. They imply that the in vivo expression of NDM may not confer clinical resistance to all cephalosporin and carbapenem antibiotics as predicted by in vitro testing but other resistance mechanisms need to be present to generate a resistant phenotype. As such, previously abandoned therapies, particularly carbapenems and beta-lactamase inhibitor combinations, may retain utility against infections caused by NDM producers. Twit Text FOAVip Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibiotics ????Infect Drug Resist http://www.kidney.de/pget.php?&tw=1&pmid=26345624 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26345624 #FOAvip English Wikipedia <ref>{{Cite pmid|26345624}}</ref> Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibiotics #MMPMID26345624 Zmarlicka MT; Nailor MD; Nicolau DP Infect Drug Resist 2015[]; 8 (ä): 297-309 PMID26345624show ga Since the first New Delhi metallo-beta-lactamase (NDM) report in 2009, NDM has spread globally causing various types of infections. NDM-positive organisms produce in vitro resistance phenotypes to carbapenems and many other antimicrobials. It is thus surprising that the literature examining clinical experiences with NDM does not report corresponding poor clinical outcomes. There are many instances where good clinical outcomes are described, despite a mismatch between administered antimicrobials and resistant in vitro susceptibilities. Available in vitro data for either monotherapy or combination therapy does not provide an explanation for these observations. However, animal studies do begin to shed more light on this phenomenon. They imply that the in vivo expression of NDM may not confer clinical resistance to all cephalosporin and carbapenem antibiotics as predicted by in vitro testing but other resistance mechanisms need to be present to generate a resistant phenotype. As such, previously abandoned therapies, particularly carbapenems and beta-lactamase inhibitor combinations, may retain utility against infections caused by NDM producers. äImpact of the New Delhi metallo-beta-lactamase on beta-lactam antibiot(epmc).pdf DeepDyve Pubget Overpricing